Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Weight-Loss Drugs
Quick Look
- Novo Nordisk has filed a lawsuit in the US against Eli Lilly, accusing its rival of false advertising regarding the superiority of its weight-loss drugs, Mounjaro and Zepbound.
- Novo Nordisk claims Eli Lilly compared lower doses of Novo Nordisk's drugs with higher doses of its own, omitting newer options.
AI-generated summary
Why It Matters
Novo Nordisk, maker of Wegovy and Ozempic, has initiated legal action against Eli Lilly, maker of Mounjaro and Zepbound, over alleged false advertising.
The maker of Wegovy and Ozempic, Novo Nordisk, has launched legal action accusing its arch rival Eli Lilly of false advertising in suggesting its weight-loss drugs perform better.
The Danish company filed a lawsuit in the US on Tuesday claiming Eli Lilly, which makes Mounjaro and Zepbound, deployed ad campaigns to "create the misleading impression that Eli Lilly's medicines are superior".
Novo said its competitor compared the highest approved doses of its medicines for obesity and type-2 diabetes with lower doses of Novo Nordisk's, while omitting newer, higher-dose options.
Eli Lilly hit back at the claims and said it stood "firmly behind our advertising".
"It is truthful, it is transparent, and it is grounded in the most direct scientific evidence available - exactly what patients deserve. We will continue to focus on the science and defend against this lawsuit vigorously," a spokesperson for the company said.
Open Questions
- What specific ad campaigns are cited in the lawsuit?
- What are the exact damages sought by Novo Nordisk?
- How will the court proceedings unfold?
